Eyal Lifschitz

Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA.

Peregrine Ventures Management Ltd (Peregrine Ventures) is a venture capital firm founded in 1999 by Eyal Lifschitz and Boaz Lifschitz. The firm is headquartered in Or Yehuda, Israel.

Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel.

Peregrine Ventures Management Ltd (Peregrine Ventures) is a venture capital firm founded in 1999 by Eyal Lifschitz and Boaz Lifschitz. The firm is headquartered in Or Yehuda, Israel.

Valtech Cardio Ltd. develops devices for mitral valve repair and replacement. It specializes in the development of devices for mitral and tricuspid valve repair and replacement. The firm also offers full in-house development, manufacturing and clinical research capabilities, and patent applications. The company was founded by Amir Gross and Yossi Gross in March 2005 and is headquartered in Or Yehuda, Israel.

N.L.T Spine Ltd. develops spine surgery instrumentation and implants for treating degenerative spinal conditions. Its products include PROW FUSION and eSPIN System. The company was founded in 2006 by Didier Toubia and Tzony Siegal and is headquartered in Kfar Saba, Israel.

N.L.T Spine Ltd. develops spine surgery instrumentation and implants for treating degenerative spinal conditions. Its products include PROW FUSION and eSPIN System. The company was founded in 2006 by Didier Toubia and Tzony Siegal and is headquartered in Kfar Saba, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Neovasc Medical Ltd. develops medical devices for the treatment of refractory angina. It offers minimally invasive treatment for Ischemic heart disease. The company was founded in 2002 by Boaz Lifschitz and is headquartered in Or Yehuda, Israel

N.L.T Spine Ltd. develops spine surgery instrumentation and implants for treating degenerative spinal conditions. Its products include PROW FUSION and eSPIN System. The company was founded in 2006 by Didier Toubia and Tzony Siegal and is headquartered in Kfar Saba, Israel.

N.L.T Spine Ltd. develops spine surgery instrumentation and implants for treating degenerative spinal conditions. Its products include PROW FUSION and eSPIN System. The company was founded in 2006 by Didier Toubia and Tzony Siegal and is headquartered in Kfar Saba, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel.

Cordio Medical Ltd. engages in the provision of solutions for monitoring health conditions through speech analysis. The company was founded by Sigal Kremer Tal, Ze'ev Schlik, Shelly Lotan, and Aviv Lotan in 2013 and is headquartered in Or Yehuda, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel.

Valtech Cardio Ltd. develops devices for mitral valve repair and replacement. It specializes in the development of devices for mitral and tricuspid valve repair and replacement. The firm also offers full in-house development, manufacturing and clinical research capabilities, and patent applications. The company was founded by Amir Gross and Yossi Gross in March 2005 and is headquartered in Or Yehuda, Israel.

Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel.

Peregrine Ventures Management Ltd (Peregrine Ventures) is a venture capital firm founded in 1999 by Eyal Lifschitz and Boaz Lifschitz. The firm is headquartered in Or Yehuda, Israel.

Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel.

Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel.

Valtech Cardio Ltd. develops devices for mitral valve repair and replacement. It specializes in the development of devices for mitral and tricuspid valve repair and replacement. The firm also offers full in-house development, manufacturing and clinical research capabilities, and patent applications. The company was founded by Amir Gross and Yossi Gross in March 2005 and is headquartered in Or Yehuda, Israel.

Valtech Cardio Ltd. develops devices for mitral valve repair and replacement. It specializes in the development of devices for mitral and tricuspid valve repair and replacement. The firm also offers full in-house development, manufacturing and clinical research capabilities, and patent applications. The company was founded by Amir Gross and Yossi Gross in March 2005 and is headquartered in Or Yehuda, Israel.

N.L.T Spine Ltd. develops spine surgery instrumentation and implants for treating degenerative spinal conditions. Its products include PROW FUSION and eSPIN System. The company was founded in 2006 by Didier Toubia and Tzony Siegal and is headquartered in Kfar Saba, Israel.

N.L.T Spine Ltd. develops spine surgery instrumentation and implants for treating degenerative spinal conditions. Its products include PROW FUSION and eSPIN System. The company was founded in 2006 by Didier Toubia and Tzony Siegal and is headquartered in Kfar Saba, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA.

Peregrine Ventures Management Ltd (Peregrine Ventures) is a venture capital firm founded in 1999 by Eyal Lifschitz and Boaz Lifschitz. The firm is headquartered in Or Yehuda, Israel.

Peregrine Ventures Management Ltd (Peregrine Ventures) is a venture capital firm founded in 1999 by Eyal Lifschitz and Boaz Lifschitz. The firm is headquartered in Or Yehuda, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

N.L.T Spine Ltd. develops spine surgery instrumentation and implants for treating degenerative spinal conditions. Its products include PROW FUSION and eSPIN System. The company was founded in 2006 by Didier Toubia and Tzony Siegal and is headquartered in Kfar Saba, Israel.

Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel.

N.L.T Spine Ltd. develops spine surgery instrumentation and implants for treating degenerative spinal conditions. Its products include PROW FUSION and eSPIN System. The company was founded in 2006 by Didier Toubia and Tzony Siegal and is headquartered in Kfar Saba, Israel.

Peregrine Ventures Management Ltd (Peregrine Ventures) is a venture capital firm founded in 1999 by Eyal Lifschitz and Boaz Lifschitz. The firm is headquartered in Or Yehuda, Israel.